Best of NACLC 2025 Webinar Enduring-Best of NACLC 2025

Video Transcription

Video Summary

The ISLAC webinar "Best of NACLC 2025" featured three expert presentations addressing key advances in lung cancer research and treatment. Dr. Hari Keshava discussed a study comparing segmentectomy and lobectomy in peripheral, small (≤3cm) non-small cell lung cancers (NSCLC) with occult lymph node metastases. The retrospective analysis showed non-inferior 10-year overall and recurrence-free survival for segmentectomy versus lobectomy, suggesting segmentectomy as a viable option, though limitations exist regarding lymph node assessment and neoadjuvant therapy data.<br /><br />Dr. Su-Lin Wu highlighted the importance of family history, sex, and ancestry in lung cancer risk, particularly among women and low-exposure smokers—a growing but underscreened group. Her large retrospective cohort demonstrated that 75% of lung cancer patients had a family cancer history, independent of smoking status, and showed sex and ancestry influence on risk and tumor genomics. She advocated for precision risk assessment incorporating these factors to improve early detection and screening equity.<br /><br />Dr. Stephen Liu presented updated data on Zenocortuzumab, a HER2/HER3 bispecific antibody targeting NRG1 fusion-positive advanced NSCLC—a rare but aggressive subtype. The phase 2 ENERGY trial showed meaningful response rates (~31-35%), durable responses, and favorable safety in both treatment-naïve and previously treated patients. Liu emphasized RNA sequencing for optimal NRG1 fusion detection and the potential for Zenocortuzumab as frontline therapy.<br /><br />The webinar concluded with discussions on clinical implications, screening guideline evolution, and the need for comprehensive molecular testing and family history integration in lung cancer care.

Keywords

ISLAC webinar

NACLC 2025

lung cancer research

segmentectomy vs lobectomy

non-small cell lung cancer

family history and lung cancer risk

precision risk assessment

Zenocortuzumab

NRG1 fusion-positive NSCLC